Abdi Ibrahim Otsuka (AIO) is a 50-50 joint venture between the Turkish Abdi Ibrahim and Japanese Otsuka. AIO, as a fusion between a Turkish market leader and a leading global innovator, markets Otsuka’s innovative products in Turkey, where the strength of the Abdi Ibrahim brand is significant.
Contact Details
Reşitpaşa Mahallesi,
Eski Büyükdere Caddesi No: 4
Maslak – Sarıyer 34467
İstanbul
Phone – 212 366 8400
www.aio.com.tr
Lih-Chung Chien, Chairman of the Taipei Exchange (TPEx), highlights the Exchange’s support for SMEs and innovative sectors via a three-tiered market, flexible IPO rules, and the Technology-Based Enterprise mechanism. Taiwan’s…
Christine Baeder, President of USA and LATAM at Apotex, discusses the company’s evolution following private equity investment, its Generics Plus strategy, and the critical role of the US market. She…
Bristol Myers Squibb (BMS), faced with patent expiries for its two largest historical revenue-generators, is racing to replace them. The US giant is re-entering the hot-again neuroscience space, as well…
Nasha Fitter, a tech entrepreneur and CEO of the FOXG1 Research Foundation, discusses the radical shift in drug development led by a new generation of sophisticated parent-entrepreneurs. Following her daughter’s…
Carlos Abelleyra leads Medix, a 70-year-old Mexican pharmaceutical company undergoing a major strategic transformation. Since 2024, he has diversified the firm beyond its historical obesity focus, establishing divisions in vitamins,…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Insilico Medicine’s partnership with Hengtai Biotech to co-develop an AI-discovered NLRP3 inhibitor for CNS disorders and Ellipses Pharma’s licensing…
Adriana Herrera, CEO of Pierre Fabre Pharmaceuticals Inc, discusses Pierre Fabre’s dedicated expansion into the US market and the unique strategies guiding its next phase of growth. Drawing on more…
Vivian Kuo, General Manager at UCB, brings over two decades of pharmaceutical industry expertise across medical affairs, marketing, corporate strategy and commercial excellence. Having spent seven years at UCB, progressing…
In recent times, French pharma industry associations have been arguing vociferously about the need to proactively ‘re-industrialise’ French pharma to counter the distortionary impact of protectionist policies and massive state…
Dr Said Ismail, geneticist and professor of genomics at Hamad Bin Khalifa University, reflects on his role as the founding director and one of the architects of the Qatar Genome…
William Hait, Chief Scientific Advisor of the American Association for Cancer Research (AACR) and Chair of AACR’s Scientific Advisory Council, highlights the society’s position within the global oncology ecosystem as…
Global advances in rare blood disorders increasingly hinge on where evidence is generated, how patients are followed, and whether innovation reaches beyond a limited few. Khaled Musallam describes how clinical…
Under Dave Huang’s leadership, Ferring Taiwan has evolved from organisational recovery to sustained performance and regional relevance. The discussion that follows examines how disciplined focus, early engagement with innovation, and…
ANSM’s Director General Catherine Paugam-Burtz offers a clear view of how France’s medicines agency is adapting to a fast-shifting landscape. She discusses ANSM’s role within the European regulatory system, the…
Marco Billi, International CEO of Eurofarma, shares his perspective on the company’s evolution from a Brazilian CMO (Contract Manufacturing Organisation) into one of Latin America’s most internationally active pharmaceutical groups.…
Rainer Westermann offers a sobering take on Europe’s declining global status as both a source and recipient of biopharmaceutical innovation. He argues that the time for a paradigm shift in…
Tony Zook reflects on how decades in pharmaceutical leadership inform his perspective on diagnostics as the backbone of precision oncology. This discussion traces NeoGenomics’ evolution from a haematology specialist to…
Healthcare systems across the world continue to struggle with fragmentation, rising costs and reactive models of care that intervene too late. Dimitris Moulavasilis, Group CEO of M42, outlines how an…
Writing in the January 2026 edition of DIA Global Forum, Mariana Socal and Antonio J. Trujillo from the Johns Hopkins Bloomberg School of Public Health and Rachel Goode of Fresenius…
In 2024, Taipei Medical University reached a defining milestone. President Mai-Szu Wu oversaw a full digital transformation linking seven affiliated medical institutions and more than 3,000 beds into a unified…
Ophthalmology is a booming niche, with investment flowing in, M&A up, and a burgeoning cast of biotechs – including the three European leaders profiled below – vying for a share…
Taiwan’s clinical research ecosystem has evolved rapidly in recent years, reflecting Asia’s growing role in global drug development. Samuel Su, Founder and CEO of Bestat Pharmaservices, discusses how the organisation…
Professor Samuel Au, Founder and CEO of Cornerstone Robotics, recounts his journey from business to academic research to building one of Asia’s most promising surgical robotics ventures. He explains how…
Taiwan is entering a pivotal phase in its healthcare evolution, and Roche’s leaders in Taiwan outline how the convergence of global expertise, advanced diagnostics and innovative therapeutics can accelerate that…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Pfizer’s US$2.1B licensing deal with Fosun Pharma for an oral GLP-1 agonist, Bao Pharmaceuticals’ 129% surge on its HKEX…
Will Hsu leads Sandoz operations across Taiwan, Hong Kong, and Macao, managing a portfolio spanning both generics and biosimilars in markets characterised by universal healthcare and significant budget constraints. With…
From factory automation in Silicon Valley to scalable service robotics embedded in daily care, Roy Long Hei’s journey with Robocore reflects a disciplined belief that technology must prove itself in…
Hong Kong is at a strategic inflection point as it seeks to redefine its role in global life sciences through regulatory credibility, institutional design, and long-term positioning between China and…
Raymond Le Moign leads one of Europe’s largest university hospital centres at a moment when healthcare systems are being forced to rethink how they organise care, innovation, and accountability. Drawing…
Roche Diagnostics Hong Kong is entering a defining phase as the city accelerates its shift toward primary care, early detection and data-driven decision making. In this interview, General Manager Ronald…
As rare disease science accelerates, regulators face growing pressure to adapt without compromising rigour. In this interview, Amy Comstock Rick explains how the FDA Rare Disease Innovation Hub is strengthening…
In less than a decade, the Abu Dhabi Stem Cells Center has emerged as a central pillar in the UAE’s ambition to build a fully integrated ecosystem for advanced therapies.…
Siegfried Gschliesser, co-founder and CEO of Anya Biopharm, has spent over two decades shaping the pharmaceutical landscape in Asia. Under his guidance, Anya has pioneered a proprietary oral peptide delivery platform,…
Charlene Son Rigby, CEO of Global Genes, shares her insights on the rapidly evolving rare disease landscape. She highlights exciting developments such as patient-driven research and development and the future…
Professor Chak-sing Lau, BBS, JP, is Vice-President & Pro-Vice-Chancellor (Health) and Dean of Medicine at The University of Hong Kong (HKU). He leads HKU’s Li Ka Shing Faculty of Medicine…
Healthcare is finally moving from a reactive “machine” to a proactive shield. In the latest issue of ISPOR’s Value & Outcomes Spotlight, Editor-in-Chief Zeba M. Khan, PhD, examines how Real-World…
Spiro Gavaris, President of Lupin’s US generics business, shares a candid assessment of the shifting dynamics shaping today’s generic and biosimilar landscape. He outlines how Lupin is positioning itself for…
Basil Khalil, Vice President of Operations at FedEx, highlights the company’s expansion of healthcare logistics in Latin America, including CEIV Pharma-certified facilities, dedicated flights, and end-to-end cold-chain infrastructure. Investments in…
Anirvan Dutt Chaudhuri, General Manager of Novo Nordisk Hong Kong, brings nearly 15 years of commercial leadership experience across global markets including Denmark, Switzerland, the US, Turkey, and now Hong…
Kelly LoBianco, founding director of the Los Angeles County Department of Economic Opportunity, discusses how the agency is driving growth of the region’s life sciences sector. She outlines LA County’s…
Latin America faces one of the most complex healthcare landscapes in the world, where fast-growing demand collides with deep structural inequities and limited resources. In this interview, Fabrizio Signorin, President…
How can mid-sized European pharmaceutical companies, which lack the scale of both Big Pharma and the major generics players, compete in a country like France? Norgine – a specialist player…
How leadership choices translate into lasting impact is the central theme of this conversation with Grant Hu. From reshaping Eisai Taiwan’s organisation to navigating access, innovation, and policy engagement, the…
Professor Chi-Huey Wong serves as President of the Institute for Biotechnology and Medicine Industry (IBMI) in Taiwan, bringing decades of distinguished experience from top-tier US research institutions including MIT, Scripps…
Dr Jung-Chi Liao, CEO and Founder of Syncell, explains how his company is creating a new category in protein identification through its microscopy-guided protein extraction technology. Trained as a mechanical…
Professor Yun-Ching Fu serves as Superintendent of Taichung Veterans General Hospital, Taiwan’s largest national medical centre in the central region. A paediatric interventional cardiologist by training, Professor Fu established Taiwan…
Jazz Pharmaceuticals’ footprint in France has accelerated over recent years, driven by a sharper focus on rare and complex diseases, a sequence of strategic acquisitions and a growing role in…
Denmark and France are intensifying their cooperation in life sciences at a time when resilience, innovation and industrial capacity have become strategic priorities for Europe. In this interview, Hanne Fugl…
For decades, the Middle East has faced a disproportionately high burden of rare genetic disorders, fuelled both by deep-rooted cultural practices and an overreliance on Western genomic data. Fast forward…
Nick Wang, General Manager of Daiichi Sankyo Taiwan, has more than 25 years’ experience across clinical research and commercial leadership. Since joining the company in 2020, he has led the…
Dr Anthony Letai reflects on how a career spanning cancer biology, clinical oncology, and translational research is shaping his early priorities as Director of the National Cancer Institute. The conversation…
Genethon sits at the forefront of a fast-accelerating moment in gene medicine, where decades of foundational research are now translating into clinical progress across rare liver, neuromuscular, immune and ophthalmic…
Chris Peetz, co-founder and CEO of Mirum Pharmaceuticals, reflects on the company’s journey from rescuing overlooked rare disease programs to building a growing global pharmaceutical company. He discusses Mirum’s expanding…
When Marc de Garidel joined AbiVax as CEO in 2023, the firm had very recently teetered on the brink of bankruptcy. Now, less than three short years later, he leads…
At a moment when rare disease policy, diagnostics, and patient-driven research are converging, Danielle Carnival sets out a clear vision for the role of the Undiagnosed Diseases Network Foundation. Drawing…
Ramon Parsons, Director of the Mount Sinai Tisch Cancer Center, reflects on four decades of progress in oncology – from molecular genetics to immunotherapy and cellular therapies – and the…
As healthcare systems across the GCC accelerate their focus on innovation, access, and advanced therapies, Novartis is positioning the region at the centre of its long-term strategy. Mohamed Ezz Eldin…
Fernando Almeida, EVP China & International Markets, discusses his global pharma career and Chiesi’s evolution into a high-performing, innovation-led group. He highlights strong double-digit growth, disciplined investment, and expansion across…
Sabrina Chan, Senior Executive at HKAPI, highlights progress in Hong Kong’s biomedical ambitions, including establishing an independent regulator, expanding clinical trial capacity via the Greater Bay Area Clinical Trial Institute…
Gustavo Pelizzari leads Elea, Argentina’s largest pharmaceutical company by sales volume, employing 1,350 people. Under his leadership, Elea has achieved the unique distinction of simultaneously leading both the retail pharmaceutical…
Cancer drug development has produced an abundance of therapies, yet outcomes in solid tumours remain constrained by resistance and relapse. In this interview, Zaiqi Wang, Chairman and CEO of InxMed,…
From the perspective of international pharmaceuticals developers, Latin America can be considered a region of exceptional potential owing to solid market fundamentals and significant untapped opportunities. “I am convinced that…
Neil F. McFarlane, President and CEO of Zevra Therapeutics, reflects on how his experiences in clinical practice, military service, and leadership roles across biotech and mid-sized pharma come together and…
When it comes to pharmaceutical exports, Latin America has historically been confined to the margins of the global life science industry. In 2023, the region accounted for a mere one…
North Carolina has become a focal point for the next phase of biopharmaceutical manufacturing, and FUJIFILM Biotechnologies is placing a significant bet on that momentum. Laurie Braxton discusses how the…
Frederic Collet, Chairman of FIAC (La Filière Intelligence Artificielle et Cancers), leads a pioneering public-private consortium bringing together nine of the world’s most innovative oncology companies with France’s public health…
France may have ceded Europe’s top spot for the sheer number of clinical trial starts to Spain in 2023, but it remains one of Europe’s most strategically valuable destinations for…
Manisha Balwani is Chief of the Division of Medical Genetics and Genomics at Icahn School of Medicine at Mount Sinai, where she leads programs spanning genetic screening, diagnosis, clinical trials,…
Patients and carers with lived experience of a disease have valuable insights to share with physicians and drug developers alike. This is especially true of rare diseases, defined in the…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Trinomab preparing for a STAR Market IPO to raise RMB 1.5 billion for its monoclonal antibody portfolio, including first-in-class…
Asia is emerging as a critical frontier in oncology research, yet much of global drug development continues to overlook the region’s specific clinical needs. At the National Cancer Center Japan,…
Ingo Brandenburg, managing director of Bayer Taiwan, brings over two decades of international pharmaceutical experience spanning Asia, Latin America, and Europe. With previous leadership roles, he has cultivated a deep…
As metabolic liver disease rises rapidly up the global health agenda, Professor Cyrielle Caussy stands at the intersection of clinical care, translational research, and therapeutic innovation. A Professor of Nutrition…
Hung Lai Wu, Chairperson of the Taiwan Alliance of Patients’ Organisations (TAPO) and a home dialysis patient for 18 years, has transformed personal experience into systemic advocacy. Since becoming a…
The FDA’s Sarah Yim discusses the evolving regulatory landscape for biosimilars in the US, the shift toward analytical-heavy reviews over large clinical studies, the legislative push to simplify interchangeability, and…
Developing effective CAR-T therapies for T-cell malignancies remains one of the most technically challenging frontiers in cell therapy. Dr Lin Yang of PersonGen Biotherapeutics discusses the company’s progress with its…
Writing in the January 2026 edition of DIA’s Global Forum, Samantha Holmes and Fiona Adshead of the Sustainable Healthcare Coalition argue that climate change is already reshaping healthcare and the…
Founded by Dr Helen Yang and Dr Peter He, Oricell Therapeutics stands at the forefront of next-generation cell and gene therapy innovation. Built on a comprehensive platform that integrates antibody…
ISPOR’s Rob Abbott traces AI’s evolution in healthcare from early expert systems to today’s machine learning and large language models, arguing that AI is now central to health economics and…
Fernando Zarate, Vice President of Bausch Health’s Latin American operations, outlines the company’s strategic positioning across the region. With 35 years in the industry and nearly two decades at Bausch…
ImmunAdd’s Dr Pi-Hui Liang discusses her transition from academic research to entrepreneurship, driven by the critical shortage of commercially available vaccine adjuvants. With a proprietary saponin-based platform addressing supply chain…
Yenchen Huang, Head of Investment, VP at Diamond Biofund, one of Taiwan’s pioneering evergreen venture capital funds focused on life sciences, our interviewee brings a unique perspective combining scientific training…
Korea, already one of the world’s top clinical research destinations, is looking to boost the efficiency of its clinical trial processes even further by launching K-CThub, a one-stop digital platform…
Some of the top recent stories from pharma and healthcare in the Middle East and Africa, including Saudi Arabia’s pharma pitch to US investors, a new fund to bring forward…
Precision medicine increasingly depends on diagnostics that can keep pace with therapeutic innovation while remaining accessible in real-world care. Jonathan Arnold reflects on how QIAGEN approaches oncology and emerging hereditary…
Alnylam is reshaping therapeutic possibilities through RNA interference, and France has become one of the strategic environments where this shift is most visible. In this interview, Jean-Baptiste Caquelin reflects on…
Biogen’s transformation into a rare disease-focused organisation is reshaping how innovation reaches patients in the GCC. Diederik Kok, the company’s GCC Head reflects on how global strategy translates into regional…
With over two decades of global pharmaceutical experience at Eli Lilly and Allergan, Dr Jimmy Chang returned to Taiwan to lead TaiMed Biologics, Taiwan’s first biotech to successfully commercialise a…
Ricardo Amtmann, President of Sanfer Group, discusses the company’s evolution from a licensing-dependent operation into Latin America’s most vertically integrated pharmaceutical enterprise. With nearly 14,000 employees across the region, Sanfer…
Pei-Jiun Chen, CEO and President of Mycenax, outlines the company’s evolution into a focused, end-to-end biologics CDMO with deep roots in development excellence and GMP manufacturing. She highlights Japan as…
Rare diseases remain among the most complex and least visible challenges facing healthcare systems, particularly in regions where genetic factors amplify the burden. In this conversation, Ahmed Salem, Head of…
Valued fifth globally in terms of overall revenues and enjoying year-on-year growth rates exceeding five percent, the French pharma market is undeniably one of the great global life science powerhouses,…
Matt Heck, founder and CEO of Sentynl Therapeutics, outlines the company’s acquisition-led rare disease strategy following its integration into Zydus Group in 2017. He discusses building a focused portfolio of…
Rare diseases in the Middle East and Africa are no longer an afterthought. As regulatory frameworks mature and governments demand deeper partnership, access, science and local commitment are being redefined.…
Cardiff Advisory’s David H. Crean outlines how the 2026 JP Morgan Healthcare Conference signaled a shift from sector reset to disciplined re-acceleration in global biopharma. Dr Crean explores investor sentiment,…
Ahead of this year’s International Women’s Day on March 8th, Unjela Kaleem highlights the disproportionate impact of cancer on women, especially those in developing countries. Kaleem – drawing on 20+…
Born from personal tragedy, Imagine for Margo has evolved into a pan-European force reshaping how childhood cancers are researched, funded, and brought to the policy agenda. Drawing on a parent’s…
Dr Chen-Yu Cheng, founder and chairman at Formosa Laboratories & Pharmaceuticals, is leading a strategic transition from generic API manufacturing toward high- value CDMO services and innovative drug development. By…
Dr Tom Tang, CEO of Maxima, discusses the company’s strategic positioning in the surgical energy device market, Taiwan’s emerging role in global medical technology manufacturing, and his vision for creating…
Dr Shuling Cheng is steering Oneness Biotech through a pivotal transition from a Taiwan-based research organisation to a globally focused commercial company. After 25 years in US biotech and medtech,…
John Murphy III, President and CEO of the Association for Accessible Medicines (AAM), argues that 2026 represents a pivotal moment for the United States to reclaim leadership in biosimilars. He…
France’s historical contribution to medical research is almost unparalleled globally, with 13 winners of the annual Nobel Prize for Physiology or Medicine, and even more for Chemistry. Most famously, Louis…
Suzhou’s bioBAY has emerged as one of China’s most dynamic biotechnology clusters, bringing together hundreds of biotech and medtech companies within an ecosystem designed to support the full innovation cycle,…
Sabrina Zimmerman, General Manager for Taiwan, Hong Kong, and Macau and APAC (excluding Japan) Portfolio Head at Biogen, shares her perspective on the company’s expanding presence in Asia and its…
EnCureGen’s founder Dr Aimin Hui draws on a career spanning oncology, molecular biology and global R&D leadership to pursue the next generation of mRNA therapeutics. His role in driving the…
The United States sits at a turning point in allergy care, shaped by decades of legacy practice and a growing demand for disease-modifying solutions. In this conversation, Peter Halling outlines…
Sean Chang, CEO of Locus Cell, explains how his clinical CAR-T background led him to build a Taiwan-based CDMO for advanced cell therapies. The company is scaling Southeast Asia’s largest…
France’s patient advocacy network is one of Europe’s most well-developed and formalised. Patient advocacy groups – including the three featured below – fill in research, care, and support gaps left…
2026 could mark a turning point for biosimilar adoption in the US. By scrapping requirements for redundant clinical trials and pushing Congress to end the “Interchangeable” label, the FDA has…
Jayashri Kulkarni Managing Director of Johnson & Johnson Taiwan, brings 27 years of experience across pharmaceuticals and medical technology in Asia Pacific. Since assuming her Taiwan role , she has…
In 2024, contract manufacturers WuXi Biologics and WuXi AppTec were catapulted into global consciousness as two of five Chinese service providers deemed a US national security threat in a draft…
Vantive’s Gary Wong shares insights into the company’s evolution from Baxter’s kidney care business into a standalone, vital organ therapies organisation. He discusses the challenges of building a new brand…
As global pharmaceutical strategies continue to shift, Ali Sleiman reflects on how Genesys Pharmaceuticals is being built as a disciplined execution platform for the Middle East and Africa. The interview…
David Barrett has led the American Society of Gene & Cell Therapy (ASGCT) since 2018, guiding its evolution into the leading professional body for scientists, clinicians, industry leaders and patient…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Ribo Life Science raising over HKD 1.8 billion through its Hong Kong IPO, and Insilico Medicine signing a US$…
Taiwanese biotech Caliway is trying to redefine fat reduction as measurable medicine. Founded in 2012, Caliway has advanced its first-in-class candidate CBL-514 into pivotal Phase III development in the US,…
Stéphane Legastelois has spent 35 years bridging science and business. After founding Indicia, he transitioned to healthcare investing, backing 30 early-stage companies, mainly in Lyon, and now heads up 33…
Thomas Gibbs, EVP and President of Lundbeck US, details his three-decade industry journey before taking the reins of the enterprise’s most strategic market. Accounting for over half of global revenues,…
The TGPA’s Tiffany Chen brings over three decades of experience at the intersection of pharmaceuticals, public policy, and industry development. In her current role, she leads advocacy efforts to strengthen…
Diego Ocampo, Vice President of Technology at Neolpharma and President of the Mexican Foundation for Health Innovation (INCIDE), represents a new generation of pharmaceutical leadership combining global perspective with regional…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta includes Zelgen Biopharm licensing its CD3×DLL3 TCE to AbbVie in a deal worth over US$1.2B, with milestone payments and tiered…
Writing in the March 2026 edition of DIA’s Global Forum magazine, PharmCube’s Juan Valencia looks back on a record year for drug approvals in China, and what it means for…
Crystal S. Denlinger, MD, serves as CEO at the National Comprehensive Cancer Network® (NCCN®), where she oversees the development of evidence-based, expert consensus-driven clinical practice guidelines that shape cancer care…
Rob Abbott, CEO of ISPOR—The Professional Society for Health Economics and Outcomes Research (ISPOR) provides an update on the organisation’s activities since taking up the role in 2023, including the…
Matt Shaulis, General Manager for North America at BeOne Medicines, discusses the company’s rapid rise as a global oncology leader and its growing impact in the US. He explains how…
Dr Carlos Prada, Director of the Edwards Family Division of Genetics and Rare Diseases at Ann & Robert H. Lurie Children’s Hospital of Chicago, discusses how earlier diagnosis, coordinated care…
CK Life Sciences, under the leadership of CEO Lance Yuen, is reshaping its identity through a renewed focus on early-stage oncology innovation powered by next-generation cancer vaccines, AI-enabled design and…
Laurence Peyraut serves as Director General of LEEM (Les Entreprises du Médicament), France’s pharmaceutical industry association representing 270 companies ranging from small French generic manufacturers to major multinational innovators. With…
Dr Ethan Shen moves comfortably between the clinic, the laboratory, and capital markets, and this conversation reflects that rare vantage point. He explains how YD Bio is built not as…
From cancer treatments to cardiovascular drugs, access to innovative medicines in South America lags behind developed market norms with patients forced to endure considerable delays for therapies that are already…
Dr Cyrus Yang, CEO of Taiwan Bio Therapeutics, outlines how he transformed the company – founded in 2014 with proprietary MSC‑expansion technology – into a global innovator in cell and gene therapy.…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include Lynk Pharmaceuticals and Bao Pharmaceuticals advancing IPO plans on HKEX, Crescent Biopharma entering a US$185M oncology partnership with Kelun-Biotech,…
Kim Moran, SVP & Head of US Rare Disease at UCB, discusses how the company is building on its long-standing heritage in neurology to expand into rare and ultra-rare conditions.…
Since arriving at Organon Taiwan two years ago, Robert Mitchell has focused on growing patient access, revenue, and investments while strengthening the team. Robert explains how he is prioritising government…
Latin America’s largest and most dynamic pharma market is booming. Despite sluggish macroeconomic growth, agile local firms are consolidating their positions to serve Brazilian patients, while a spate of technology…
Built around an engineering mindset and a clear view of where a smaller biotech can compete, Pharmosa is pursuing a differentiated path in pulmonary hypertension and related rare diseases through…
Ipsen France is navigating a pivotal moment. The affiliate sits at the intersection of global pipeline expansion, rising expectations for access and renewed national ambition around industrial sovereignty and innovation.…
Lian-Yu Chen, Director General of Taiwan’s National Health Insurance Administration, combines expertise in clinical psychiatry, public health, and governmental leadership. A PhD graduate of Johns Hopkins Bloomberg School of Public…
CTI EMEA Managing Director Alaa Assem is a physician, ophthalmologist and MBA holder with over 30 years of experience in pharma and clinical research organisations. Since joining CTI, he has…
Estelle Fruchet, General Manager of Shionogi France since September 2024, brings 25 years of pharmaceutical experience spanning major organisations including Roche, Gilead, and Novartis Gene Therapies. A pharmacist by training…
Biogen France is operating at a moment of profound change, where rapid advances in neurology, immunology and rare diseases intersect with shifting global dynamics on investments to innovation and new…
Has Argentina, for years one of the economic basket cases of Latin America, finally turned a corner? And is its pharma industry set for a bounce back? Firebrand TV…
Hussein Abhari, Head of the MENA region, QIAGEN, has led the company’s regional presence since 2017, spanning products for molecular research and clinical testing. His priorities focus on strengthening long-term…
China Biotech private financing in H2 2025 reflected a distinct “flight to quality,” moving from the valuation outliers of Q3 toward a disciplined clinical focus in Q4. As Dr Cathy…
Tanya Carro details Duchesnay Pharmaceutical Group’s organic expansion from its women’s health core into rare diseases and generics. Operating across three geographic pillars, the privately held firm leverages Canadian pricing…
Jack Chiu is leading Siemens Healthineers’ transformation from equipment supplier to value-based healthcare partner in Taiwan. Under the 2026–2030 “Elevating” strategy, Taiwan serves as an Asia-Pacific innovation landing pad, validating…
France and Denmark have a rich history of healthcare collaboration, from basic research to clinical trials, as well as major manufacturing investments. What links these two nations, and what are…
John Hess, Senior Vice President, Americas at Chiesi Global Rare Diseases, reflects on his career journey and the evolution of Chiesi’s dedicated rare disease organisation. In this interview, he discusses…
2025 was a year of volatility for pharma and healthcare. In particular, the speed with which the administration of Donald Trump makes (and often then changes) consequential policy decisions has…
Epidemiologist Dr Chen Chien-jen has spent decades at the intersection of scientific research and public health policy. His pioneering work on arsenic-induced health hazards informed international water safety standards, whilst…
Chung-Liang Shih, Taiwan’s Minister of Health and Welfare, brings extensive governmental experience from his tenure as Director General of the National Health Insurance Administration, where he led reforms to strengthen…
Genome editing is moving from proof of concept to clinical reality, but questions around scale, cost, and responsibility now define its future. In this interview, Brad Ringeisen outlines how the…
Dr Rania Alshami reflects on two decades in the Middle East and North Africa clinical research ecosystem, charting the region’s regulatory maturation, rare disease opportunities, and growing role in early-phase…
Skyepharma stands at a defining moment. With new shareholders, expanding high-potency and bioproduction capabilities and a sharpened focus on complex oral forms, the French CDMO is positioning itself for a…
Frank Bedu‑Addo shares his journey from scientist to co‑founder and CEO of PDS Biotechnology. He highlights promising progress across PDS’s oncology pipeline, including strategic decisions that have helped improve antitumor…
Glenn Robertelli, CEO of RI Bio, is shaping Rhode Island into a rising life sciences hub through strategic partnerships, innovative programs, and support for early-stage biotech. Despite the state’s small…
Craig Martin, CEO of the Orphan Therapeutics Accelerator (OTXL), discusses the urgent need for a new business model to rescue abandoned clinical-stage programs in the rare disease sector. He details…
Nearly two years on from our last conversation with Henry Yau, Hong Kong’s clinical trials narrative has shifted from institutional intent to operational execution. The managing director of the HKU…
As Abu Dhabi translates strategy into execution, the focus turns from platform design to operational delivery. Albarah Elkhani, COO of Integrated Health Solutions at M42, details how large-scale genomics, clinical…
Complementing the Lyon region’s strong industrial footprint is a dense network of hospital facilities, only bettered by Paris on the national level. Across 13 hospitals in the Hospices Civils de…
Lyon – recently announced as the host of BIO-Europe Spring 2027 – has long played a vital role in global health and, in 2026, it stands as one of Europe’s…
Shaped by decades across US biotech, big pharma, and China’s high-intensity innovation environment, Dr Jing Li brings a rare end-to-end perspective on how biologics move from idea to impact. In…
Jeff Allen is the President & CEO of Friends of Cancer Research, a research policy and advocacy organisation based in Washington, DC. His organisation works to accelerate the development of…
PharmaEngine is entering a defining phase as it strengthens its development-only roots while expanding into early discovery, differentiated DNA damage response programmes and AI-enabled design. In this conversation, CEO Hong-Ren…
A new chapter in vital organ care is unfolding as Vantive establishes its identity as an independent, purpose-driven leader in kidney care. With Trushar Patel stepping into an expanded leadership…
Michael Pearlmutter, CEO of the EveryLife Foundation for Rare Diseases (the EveryLife Foundation), brings a deeply personal motivation and commitment to driving meaningful change for the rare disease community. In…
After 25 years at Genzyme and Sanofi, Chris Hwang joined a biotech startup in China in 2016 to develop advanced bioprocessing technologies that reduce cost of goods while maintaining reliable…
Bringing together clinical scale, academic depth, and a strong engineering mindset, China Medical University Hospital has positioned itself as more than a care provider. In this interview, Dr Der-Yang Cho,…
Following our conversation with CEO Lance Yuen on CK Life Sciences’ strategic direction, Chief Scientific Officer Melvin Toh now takes us inside the scientific engine driving that vision forward. He…
Jerry Radich of the Fred Hutchinson Cancer Center, writing in the February 2026 edition of DIA’s Global Forum magazine, lays out a framework for taking cutting-edge cancer therapies – currently…
Dr John Chang, Chief Executive Officer of the Formosa Cancer Foundation and a distinguished medical oncologist at Chang Gung Memorial Hospital, provides a comprehensive strategic analysis of Taiwan’s oncology landscape.…
Lyon’s leading biotechs have caught the eye of global pharma in recent years, with two major acquisitions attesting to the quality and sophistication of the ecosystem and laying a path…
France is considered among the leading rare disease markets worldwide, both scientifically and organisationally. The country has cultivated a fully-fledged supporting ecosystem for rare conditions that is today regarded as…
Jerry Cheng is general manager for Illumina across Taiwan, Hong Kong, and Macau, steering the company’s expansion in three strategically significant genomics markets. With over two decades of pharmaceutical industry…
Frederic Kuo, founder and CEO of Fethiann, established the company in 2017 within Taiwan’s Hsinchu Science Park. With a PhD background and extensive experience in new drug development, Frederick has…
Pharma in 2026 will be defined by unpredictability. Executives are already being pushed by shifting policy, commercial, and scientific forces into making fast and tough strategic choices, with more to…
Dr David Chang discusses his vision for establishing the world’s premier cell and gene therapy contract development and manufacturing organisation in Taiwan. Drawing on more than 30 years of experience…
Cathy Su, General Manager for Taiwan, Hong Kong/Macau & Singapore at Gilead Sciences, reflects on her nineteen-year tenure with the biopharmaceutical company, progressing from market analytics to multi-market leadership. She…
Orla Cloak, CEO of Minaris, explains how the organisation. was formed by integrating Minaris Regenerative Medicine, a dedicated cell and gene therapy (CGT) CDMO, and WuXi Advanced Therapies, which brought…
Philip Macnabb serves as Chief Executive Officer of Curia, bringing 25 years of private equity-backed healthcare experience to his first venture into the CDMO sector. Joining in March 2023, Macnabb…
Katherine Stueland, CEO of GeneDx, describes transforming the 26-year-old NIH spinout into a scalable, patient-focused business. Leveraging the Infinity database, strategic biopharma partnerships, AI-driven interpretation, and cost-efficient exome and genome…
Raphaël Chin-Fo-Sieeuw, Vice President Life Sciences and Healthcare Americas, DHL Group outlines the Americas as a core growth region, with strong momentum in Latin America. He details DHL’s multi-billion-Euro investment…
Guy Savoir, CEO at Carnot Laboratorios, brings strategic vision to Mexico’s pharmaceutical reindustrialisation. Leading a company that has achieved balanced growth across Mexican and Latin American markets, he articulates an…
Norgine is redefining what a mid-sized European specialist can achieve, shifting from its gastroenterology heritage into a broader mix of consumer health, women’s health and rare diseases. These changes are…
European biotech’s recent struggles are well documented. Deep-pocketed investors with sufficient risk tolerance to fund potentially breakout companies are thin on the ground, and Europe is losing touch with both…
The Auvergne-Rhône-Alpes region, with Lyon at its heart, is France’s industrial heartland. Hosting over 500,000 manufacturing and manufacturing-related jobs, AURA is also the nation’s top destination the production of biologics,…
This week’s China healthcare highlights from PharmaBoardroom content partner Selesta include WuXi XDC’s acquisition of TOT Biopharm to expand ADC CDMO capabilities, Sino Biopharma’s entry into RNAi therapeutics with the…
Drawing on over two decades of leadership industry across Asia, Cecilia Qi reflects her transition from global pharma to leading DCH Auriga. She shares insights on the company’s evolution into…
With Takeda preparing for global leadership change and Taiwan rapidly upgrading its innovation and access frameworks, General Manager Alexis Lin is navigating one of the most pivotal periods in the…
Biotechnology in Taiwan is no longer a future aspiration, but an industrial system deliberately built for global relevance. In this conversation, the Chairman and CEO of the Development Centre for…
Amy Ho, General Manager of Roche Pharma Hong Kong, returns to the city with a unique blend of diagnostics and pharmaceutical experience at a moment when the healthcare system is…
Lonza’s transformation under the One Lonza Strategy comes at a moment of significant change for the global biologics and CDMO sectors. Gordon Bates, Head of Integrated Biologics, reflects on the…
Boston Scientific’s Dan Silver reflects on his global leadership journey and the evolution of the company’s presence in one of Asia’s most advanced healthcare systems. Silver discusses Boston Scientific’s growth…
Promoted to General Manager of Moderna Taiwan in 2024, Wenchi Liu brings over 20 years of pharmaceutical industry experience spanning commercial strategy and operations. Since joining Moderna in 2023, she…
Adeeb Al Attar leads Genpharm at a point where rare and advanced therapies in the Middle East face a more exacting test. Scale and ambition are no longer enough. What…
MaaT Pharma is entering a defining moment in its mission to bring microbiotherapies into areas of acute unmet need. Hervé Affagard recounts how a personal catalyst, an engineering mindset and…
Hong Kong is quietly re-engineering how clinical research is organised and delivered across one of the world’s most dynamic life-sciences regions. Through the Greater Bay Area International Clinical Trial Institute…
As Hong Kong positions itself as a regional healthcare and clinical research hub within the Greater Bay Area, multinational pharma companies are being asked to play a more active role…
Catherine Owen Adams, CEO of Acadia Pharmaceuticals, discusses how the company’s dual commercial pillars in Parkinson’s disease psychosis and Rett syndrome are delivering much-needed impact for patients with significant unmet…
This conversation with Bruno Dubois offers a clear, experience-driven perspective on how Alzheimer’s disease is being redefined, from diagnosis and biomarkers to prevention and early intervention. Drawing on decades at…
Erick Lelouche has served as President of Lyonbiopôle since February 2025, bringing more than 35 years of experience in the pharmaceutical industry across Pfizer and Boehringer Ingelheim, spanning human and…
African healthcare and pharma are moving from ambition to action. Regular PharmaBoardroom contributor Lenias Hwenda explains how, after years of over-dependence on global supply chains, fragmented regulation, and limited local…
As global vaccine development grows more complex and capital more selective, Valneva is sharpening its identity and returning decisively to its roots. The company’s decision to close its Nantes site…
Danielle Bibas leads Pierre Fabre’s operations in Brazil, overseeing three key dermo-cosmetic brands – Avène, Darrow, and Ducray – in the world’s third-largest beauty market. Since assuming the role in…
Alberto Santagostino, CEO of AGC Biologics, discusses how the company is positioning itself in an increasingly regionalized CDMO market, the strategic value of its global manufacturing footprint, and the role…
Paul Kim, a leading FDA attorney and policy expert formerly at both the FDA and the US Congress, discusses the current shifts within the American life sciences and regulatory landscape.…
Dominique Pezziardi oversees International Commercial Operations for Stallergenes Greer, a global biotechnology company specialising in allergy therapeutics. With more than 1,200 employees globally – over 600 based in France –…
France finally has a full budget for 2026, ending months of stasis, and providing a degree of certainty to industry. However, especially for pharma, continual price cuts threaten the sustainability…
As President of the Taiwan Clinical Research Association (TCRA), Tina Sun brings 25 years of pharmaceutical industry experience to bear on the evolution of Taiwan’s clinical research ecosystem. This interview…
Founded to tackle one of the most persistent blind spots in rare disease policy, the Rare Access Action Project (RAAP) focuses on what happens after FDA approval, when therapies meet…
Loretta Beine, Senior Director of Industry Development for Life Sciences, Empire State Development (ESD) explains the organization’s broader role in growing New York State’s life sciences sector beyond direct funding.…
Kyowa Kirin’s new head for France and Benelux steps into the role at a time when rare diseases, regulatory expectations and scientific modalities are all shifting at speed. In this…
Dirk van Niekerk, President and CEO of Boehringer Ingelheim South America, identifies Latin America as a pivotal growth engine. Focusing on cardio, renal, metabolic and oncology pillars, the firm is…
Taiwan, an early international market for Kyowa Kirin, now serves as a strategic hub within a Korea-Taiwan-Australia cluster. With a lean team, close government engagement, and clinical trial initiatives, Taiwan…
See our Cookie Privacy Policy Here
